Lenalidomida Stada (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering its activity. This triggers the degradation of transcription factors Ikaros and Aiolos, which leads to anti‑angiogenic effects, modulation of cytokine release, enhanced immune‑mediated tumor cell killing, and direct inhibition of malignant cell growth.

The prescribed dose of Lenalidomida Stada is individualized by the treating physician based on the specific indication, disease stage, patient’s renal and hepatic function, and any concomitant therapies. No universal dosing schedule is provided; the prescriber sets the appropriate regimen for each patient.

Lenalidomida Stada is classified as Pregnancy Category X, meaning it is contraindicated in pregnancy because of a high risk of fetal harm. It should not be used by breastfeeding mothers, and effective contraception is required for women of child‑bearing potential during treatment and for a defined period after the last dose.

To place an order, submit an enquiry on the Lenalidomida Stada product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The primary alternative to lenalidomide is thalidomide, another immunomodulatory agent. Lenalidomide generally offers a more favorable safety profile, with lower rates of peripheral neuropathy, and stronger anti‑angiogenic and immune‑modulating activity. Pomalidomide is a newer analogue that may be used after lenalidomide failure, but it can have higher hematologic toxicity.

Lenalidomida Stada should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and avoid storing it in areas with high humidity or temperature fluctuations to maintain potency.

Lenalidomida Stada is taken orally, usually with a glass of water. The tablet can be swallowed with or without food, unless the prescribing physician advises otherwise. Patients should follow the dosing schedule provided by their healthcare professional and not alter the regimen without medical guidance.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe neutropenia that can predispose to infections, hepatotoxicity indicated by elevated liver enzymes, and the possible development of secondary malignancies. Prompt reporting of any unusual symptoms to a healthcare provider is essential.

Lenalidomida Stada should not be used by pregnant women or women who may become pregnant without effective contraception. Patients with known hypersensitivity to lenalidomide or any component of the formulation should avoid it. Caution is also advised for individuals with severe renal impairment, uncontrolled infections, or a history of thromboembolic disease.